BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The announcement could shake up the market for such injections, since the shortage designation allowed compounding pharmacies ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

But regardless of what patients take them for, there is an outstanding concern: the muscle loss that often accompanies rapid ...

Muscle-sparing is particularly important in patients with heart failure as it is associated with higher mortality.

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.

Terns Pharma is in the process of developing TERN-601 for the treatment of patients with obesity. See why I rate TERN stock ...

There are several Ozempic alternatives available today, like Rybelsus, Mounjaro, Wegovy and Zepbound. Other medications may ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...